Innovation testbeds as enabling ecosystems driving nanopharmaceuticals to market

Luis Padrela; Rabah Mouras; Donal Killackey

doi:10.1016/j.drudis.2025.104433

Innovation testbeds as enabling ecosystems driving nanopharmaceuticals to market

Luis Padrela
, Rabah Mouras
, Donal Killackey

Research output: Contribution to journal › Review article › peer-review

Abstract

It is a major challenge to produce proof-of-concept (PoC) pharmaceutical nanoformulations of the required quality level, and in sufficient quantities for late preclinical and clinical testing. The creation of bespoke capabilities to assist in the translation of early stage PoC medicines could greatly reduce time and cost to bring new and innovative therapies to the market. This paper reflects on current barriers hampering the commercialization of novel nanopharmaceuticals and discusses the potential for integrated approaches to bring together existing and new processing infrastructures to de-risk and accelerate the development, manufacturing and market entry of the next-generation nanopharmaceuticals.

Original language	English
Article number	104433
Journal	Drug Discovery Today
Volume	30
Issue number	8
DOIs	https://doi.org/10.1016/j.drudis.2025.104433
Publication status	Published - Aug 2025

Keywords

critical quality attributes
drug nanoparticles
GMP
nanopharmaceutical development hubs
nanopharmaceuticals
scale-up

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drudis.2025.104433

Cite this

@article{319f3229ccb54a0eaf8d73645371e059,

title = "Innovation testbeds as enabling ecosystems driving nanopharmaceuticals to market",

abstract = "It is a major challenge to produce proof-of-concept (PoC) pharmaceutical nanoformulations of the required quality level, and in sufficient quantities for late preclinical and clinical testing. The creation of bespoke capabilities to assist in the translation of early stage PoC medicines could greatly reduce time and cost to bring new and innovative therapies to the market. This paper reflects on current barriers hampering the commercialization of novel nanopharmaceuticals and discusses the potential for integrated approaches to bring together existing and new processing infrastructures to de-risk and accelerate the development, manufacturing and market entry of the next-generation nanopharmaceuticals.",

keywords = "critical quality attributes, drug nanoparticles, GMP, nanopharmaceutical development hubs, nanopharmaceuticals, scale-up",

author = "Luis Padrela and Rabah Mouras and Donal Killackey",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s)",

year = "2025",

month = aug,

doi = "10.1016/j.drudis.2025.104433",

language = "English",

volume = "30",

journal = "Drug Discovery Today",

issn = "1359-6446",

number = "8",

}

TY - JOUR

T1 - Innovation testbeds as enabling ecosystems driving nanopharmaceuticals to market

AU - Padrela, Luis

AU - Mouras, Rabah

AU - Killackey, Donal

PY - 2025/8

Y1 - 2025/8

N2 - It is a major challenge to produce proof-of-concept (PoC) pharmaceutical nanoformulations of the required quality level, and in sufficient quantities for late preclinical and clinical testing. The creation of bespoke capabilities to assist in the translation of early stage PoC medicines could greatly reduce time and cost to bring new and innovative therapies to the market. This paper reflects on current barriers hampering the commercialization of novel nanopharmaceuticals and discusses the potential for integrated approaches to bring together existing and new processing infrastructures to de-risk and accelerate the development, manufacturing and market entry of the next-generation nanopharmaceuticals.

AB - It is a major challenge to produce proof-of-concept (PoC) pharmaceutical nanoformulations of the required quality level, and in sufficient quantities for late preclinical and clinical testing. The creation of bespoke capabilities to assist in the translation of early stage PoC medicines could greatly reduce time and cost to bring new and innovative therapies to the market. This paper reflects on current barriers hampering the commercialization of novel nanopharmaceuticals and discusses the potential for integrated approaches to bring together existing and new processing infrastructures to de-risk and accelerate the development, manufacturing and market entry of the next-generation nanopharmaceuticals.

KW - critical quality attributes

KW - drug nanoparticles

KW - GMP

KW - nanopharmaceutical development hubs

KW - nanopharmaceuticals

KW - scale-up

UR - https://www.scopus.com/pages/publications/105011163542

U2 - 10.1016/j.drudis.2025.104433

DO - 10.1016/j.drudis.2025.104433

M3 - Review article

C2 - 40675439

AN - SCOPUS:105011163542

SN - 1359-6446

VL - 30

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 8

M1 - 104433

ER -

Innovation testbeds as enabling ecosystems driving nanopharmaceuticals to market

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this